Table 1. Clinical characteristics associated with the level of prNLR.
| Variables | prNLR < 2.1 | prNLR ≥ 2.1 | p value |
|---|---|---|---|
| Sex | 0.779 | ||
| Male | 11 | 29 | |
| Female | 5 | 14 | |
| Age | 0.538 | ||
| Median | 56 | 61 | |
| Range | 39–80 | 21–80 | |
| ECOG PS | 0.067 | ||
| 0 | 9 | 12 | |
| 1 | 7 | 28 | |
| AJCC stage | 0.257 | ||
| II | 4 | 4 | |
| III | 10 | 33 | |
| IV | 2 | 3 | |
| Hepatitis | 0.928 | ||
| B | 11 | 27 | |
| Others | 5 | 13 | |
| Liver cirrhosis | 0.350 | ||
| No | 6 | 10 | |
| Yes | 10 | 30 | |
| PVTT | 0.089 | ||
| No | 10 | 15 | |
| Yes | 6 | 25 | |
| AFP | 0.708 | ||
| < 400 | 12 | 28 | |
| ≥ 400 | 4 | 12 | |
| Pretreatment CP class | 0.645 | ||
| A | 14 | 33 | |
| B | 2 | 7 | |
| GTV | 0.495 | ||
| < 214 cm3 | 11 | 31 | |
| ≥ 214 cm3 | 5 | 9 |
Abbreviations: prNLR, pre-radiotherapy neutrophil-to-lymphocyte ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; AJCC, American Joint Committee on Cancer; PVTT, portal vein tumor thrombosis; AFP, alpha-fetoprotein; CP, Child-Pugh; GTV = gross tumor volume.